27 Aug - 10 Sep 2021Rights issue
Aptahem AB is a biotechnology company whose main business model is to preclinically and clinically develop aptamer-based treatments for life-threatening, acute conditions where coagulation and inflammation interact in the disease process. The aim is to meet the global need for medicines within these conditions.
The offer in summary
Subscription period: 27 August - 10 September 2021
Subscription price: 4.80 SEK per unit
Trading in unit rights: 27 August - 7 September 2021
Issue volume: 61.8 MSEK
Unit: One (1) unit consists of four (4) shares and three (3) warrants of serie TO 7